1 Streptococcus species abundance in the gut is linked to subclinical coronary

2 atherosclerosis in 8,973 participants from the SCAPIS cohort

- 3 Sergi Sayols-Baixeras^{1,2*}, Koen F Dekkers^{1*}, Ulf Hammar¹, Gabriel Baldanzi¹, Yi-Ting Lin^{3,4}, Shafqat
- 4 Ahmad^{1,5}, Diem Nguyen¹, Georgios Varotsis¹, Sara Pita^{6,7}, Nynne Nielsen⁶, Aron C. Eklund⁶, Jacob B
- 5 Holm⁶, H Bjørn Nielsen⁶, Louise Brunkwall⁸, Filip Ottosson^{8,9}, Christoph Nowak³, Daniel
- 6 Jönsson^{8,10,11}, Dan Ericson¹², Björn Klinge^{11,13}, Peter M Nilsson^{8,14}, Andrei Malinovschi¹⁵, Lars Lind¹⁶,
- 7 Göran Bergström^{17,18}, Johan Sundström^{19,20}, Johan Ärnlöv^{3,21}, Gunnar Engström⁸, J. Gustav
- 8 Smith^{22,23,24}, Marju Orho-Melander^{8#} and Tove Fall^{1#}
- 9 *Shared first authorship
- 10 [#]Shared senior authorship
- ¹Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala
- 12 University, EpiHubben, MTC-huset, Uppsala, Sweden
- 13 ²CIBER Cardiovascular diseases (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
- 14 ³Division of Family Medicine and Primary Care, Department of Neurobiology, Care Science and
- 15 Society, Karolinska Institutet, Huddinge, Sweden
- ⁴Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical
- 17 University, Taiwan
- ⁵ Preventive Medicine Division, Harvard Medical School, Brigham and Women's Hospital, Boston,
- 19 MA, United States
- 20 ⁶Clinical Microbiomics A/S, Copenhagen, Denmark
- ²¹ ⁷The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark,
- 22 Lyngby, Denmark
- 23 ⁸Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- ⁹Section for Clinical Mass Spectrometry, Danish Center for Neonatal Screening, Department of
- 25 Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark
- ¹⁰Public Dental Service of Skåne, Lund, Sweden.
- ²⁷ ¹¹Department of Periodontology, Faculty of Odontology, Malmö University, Malmö, Sweden.
- ¹²Department of Cariology, Faculty of Odontology, Malmö University, Malmo, Sweden.
- ¹³Department of Dental Medicine, Karolinska Institutet, Solna, Sweden.
- 30 ¹⁴Department of Internal Medicine, Skånes University Hospital, Malmö, Sweden
- ¹⁵Department of Medical Sciences, Clinical Physiology, Uppsala University, Uppsala, Sweden.
- ¹⁶Department of Medical Sciences, Clinical Epidemiology, Uppsala University, Uppsala Science Park,

33 Uppsala, Sweden

- ¹⁷Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy,
- 35 University of Gothenburg, Gothenburg, Sweden
- ¹⁸Department of Clinical Physiology, Sahlgrenska University Hospital, Region Västra Götaland,
- 37 Gothenburg, Sweden
- ¹⁹Department of Medical Sciences, Clinical Epidemiology, Uppsala University, Uppsala, Sweden
- ²⁰The George Institute for Global Health, University of New South Wales, Sydney, Australia
- 40 ²¹School of Health and Social Studies, Dalarna University, Falun, Sweden
- 41 ²²The Wallenberg Laboratory/Department of Molecular and Clinical Medicine, Institute of Medicine,
- 42 Gothenburg University and the Department of Cardiology, Sahlgrenska University Hospital,
- 43 Gothenburg, Sweden

- ²³Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund,
 Sweden
- ²⁴Wallenberg Center for Molecular Medicine and Lund University Diabetes Center, Lund University,
 Lund, Sweden
- 48 WORD COUNT: 4,472

49 Abstract

50 Coronary atherosclerosis is the main pathophysiological mechanism underlying myocardial infarction. The gut microbiota has been implicated in cardiometabolic disease but its relationship with subclinical 51 coronary atherosclerosis is unknown. We identified 73 gut metagenomics species associated with 52 53 coronary artery calcium score (CACS) in 8,973 SCAPIS participants without previous cardiovascular 54 disease. Streptococcus associations were overrepresented and were validated in an independent casecontrol study together with eight non-Streptococcus spp. We further found enrichment for bacterial 55 genes linked to amino acid and carbohydrate degradation functions. Gut Streptococcus spp. were 56 associated with circulating biomarkers of inflammation and infection response, bile acids, androgenic 57 58 steroids and sphingomyelins, and were associated with their homologous species in the oral cavity, 59 which were in turn associated with oral pathologies. This study provides robust evidence of the 60 association of Streptococcus spp., with subclinical atherosclerosis and markers of systemic inflammation and infection, calling for studies re-investigating the infectious hypothesis in 61 62 atherosclerosis pathogenesis.

Atherosclerotic cardiovascular diseases (ACVD), such as ischemic heart disease and ischemic stroke, 63 are the major causes of death and disability¹. The formation of atherosclerotic plaques is a silent, 64 65 complex, and progressive process characterized by accumulation of lipids, fibrous elements, calcium minerals, and inflammatory molecules in the subendothelial space². While the underlying mechanisms 66 of atherosclerosis remain incompletely understood, it has been proposed that the gut microbiota 67 composition could contribute to accelerated atherosclerotic development by transmission of bacteria 68 69 into circulation, resulting in either subsequent direct infection of the atherosclerotic plaque or systemic inflammation associated with infection at other sites². For instance, experimental studies suggested 70 71 that oral challenge with *Streptococcus* spp. accelerates atherosclerotic plaque growth and macrophage 72 invasion³. Alternatively, certain bacteria could affect the atherosclerosis process by modulating the 73 host metabolism or interaction with dietary components to produce both beneficial and harmful molecules². Gut microbiota composition has already been linked to cardiovascular risk factors, such as 74 obesity⁴, insulin resistance⁵ and type 2 diabetes⁶, although the causal relationships remain unclear. A 75 number of case-control studies of symptomatic coronary atherosclerosis with up to 1,241 participants 76 have pointed to differences in abundance of more than 500 gut species⁷⁻¹⁵. However, the findings are 77 often not reproducible and are prone to bias; comparison groups are often non-comparable in terms of 78 medical treatment and lifestyle factors, and there is risk of reverse causation. The importance of 79 80 employing large cohorts in microbiome research of earlier phases of the atherosclerosis process are thus compelling^{7,13,14,16,17}. 81

82 Here, we identified associations between gut microbiota composition, in particular *Streptococcus* spp., 83 and asymptomatic coronary atherosclerosis, determined by computed tomography-derived coronary 84 artery calcium score (CACS), in a large cohort of middle-aged Swedes from the Swedish CArdioPulmonary bioImage Study (SCAPIS)¹⁸ and validated in a geographically distinct case-control 85 86 study of symptomatic atherosclerotic disease. Furthermore, we identified associations of gut Streptococcus spp. with circulating inflammatory and infection biomarkers. These species were further 87 associated with the corresponding oral Streptococcus spp. that in turn were associated with worse oral 88 health. In conclusion, we identify a subset of gut microbiota species with enrichment for Streptococcus 89

90 that are robustly associated with CACS, laying the foundation for future studies on causal

91 relationships and investigations of the plausibility of these species as potential intervention targets to
92 reduce cardiovascular risk.

93 **Results**

94 Large Swedish cohort profiled with deep shotgun metagenomics of fecal samples and detailed

95 coronary atherosclerosis imaging. In the current study, we took advantage of SCAPIS, a unique

96 resource for epidemiological studies combining a large sample size with extensive and in-depth

97 phenotypic information, including cutting-edge molecular techniques and direct imaging of the

98 cardiovascular disease (CVD) processes¹⁸. We selected 8,973 individuals recruited at the Malmö and

99 Uppsala sites, aged 50–64 years, with no history of symptomatic CVD. A description of the main

sociodemographic and clinical characteristics of the study population is presented in **Table 1**,

101 including the prevalence of calcified coronary plaques, measured as CACS and categorized as absent

102 (CACS=0), mild (1–100), moderate (101–400), and extensive (>400) calcification of coronary arteries.

103 The prevalence of CACS>0 in the study sample was 40.3%, comparable to the whole SCAPIS

104 population¹⁹, which in turn showed a high agreement with contrast-enhanced coronary computed

tomography angiography (CCTA), an alternate measurement of atherosclerosis¹⁹. Only 5.5% of the

106 participants with CACS=0 were classified as having any coronary atherosclerosis.

107 Gut microbiota composition and richness are associated with asymptomatic atherosclerosis and attenuated by adjustment for lifestyle factors, diet and medication. To test the primary hypothesis 108 109 that gut microbiota composition is associated with CACS at the asymptomatic disease stage, we first 110 tested whether the alpha and beta diversity measures were associated with CACS. Alpha diversity, a measure of overall species richness and evenness within each sample, was inversely associated with 111 CACS (β =-0.16 (95% confidence interval (CI) = -0.26, -0.07, p-value=8.6*10⁻⁴)) using linear 112 regression adjusting for age, sex, country of birth, center site and extraction plate (basic model). 113 However, after further adjustment for smoking, physical activity, fiber and total energy intake, and 114 self-reported medication for dyslipidemia, hypertension and/or diabetes (full model), no association 115

was observed (β =-0.04 (95% CI=-0.15, 0.06, p-value=0.38)). These covariates were included because 116 our hypothetical causal diagram indicated them as potential confounders for the microbiota-CACS 117 118 association (Extended Data Fig. 1). Further, in permutational multivariate analysis of variance (PERMANOVA), we found that beta diversity, an indicator of the overall similarity among samples, 119 differed across the CACS categories in both models, although the fully adjusted model was attenuated 120 $(r_{\text{basic}}^2=0.0007; \text{ p-value}_{\text{basic}}=1*10^{-04} \text{ vs } r_{\text{full}}^2=0.0004; \text{ p-value}_{\text{full}}=0.036)$. Pairwise comparisons revealed 121 122 that the overall microbiome composition in participants with CACS=0 was different compared to other 123 categories, with increasing distances with higher CACS classes (Figure 1 and Supplementary Table 1). These findings suggest that gut microbiome composition and richness are associated with 124 asymptomatic atherosclerosis, but that differences are partly due to differences in lifestyle factors, diet, 125 126 and medication across groups. 127 Specific species are robustly associated with subclinical atherosclerosis, especially species belonging to the Streptococcus genus. Extensive simulation studies prior to the analysis supported 128 the use of linear regression modelling for high power, interpretability, and low frequency of false 129 positive findings (Extended Data Fig. 2). We found the relative abundance of 73 out of 1,985 tested 130 131 species associated with CACS at a false discovery rate (FDR) of 5% using the basic model further 132 adjusted for Shannon diversity index. For 60 of these, the relative abundance was positively associated with CACS and for 13 negatively associated (Fig. 2a, b, d, Supplementary Tables 2 and 3). Gene-133

set enrichment analysis (GSEA) for genera revealed an overrepresentation of the *Streptococcus* genus

in the associations with a positive effect estimate (Fig. 2a, c, and Supplementary Table 4). In the full

136 model (further adjusted for Shannon diversity index), 63 species remained associated with CACS in

137 8,155 individuals with complete data on all covariates (Fig. 2a, d, and Supplementary Table 3).

138 Streptococcus anginosus, Streptococcus oralis subsp. oralis, Anaerotignum lactatifermentans,

139 Escherichia coli, and Eubacteriales sp. (internal identifier HG3A.1354) were most strongly species

140 associated with CACS based on p-value, and all of them were positively associated. To assess whether

- 141 the difference in the number of associated species between basic and full model was due to smaller
- sample size or confounding by the included covariates in the full model, we re-analyzed the 73 species

associations with the basic model restricted to the 8,155 individuals with complete data that were 143 included in the full model. This analysis showed highly correlated (Pearson correlation=0.99) but 144 145 slightly attenuated estimates compared to the full model, supporting the difference in the number of 146 associated species between basic and full model to be mainly due to lower power and to some extent 147 confounding (Supplementary Table 3 and Extended Data Fig. 3). A comparison of the main clinical characteristics of carriers and non-carriers of the most strongly associated species S. anginosus and S. 148 149 oralis subsp. oralis (Supplementary Table 5) revealed that these Streptococcus spp. were more 150 prevalent in women. Carriers had on average higher triglycerides, blood pressure, body mass index (BMI), high-sensitivity C-reactive protein (hsCRP), leukocytosis, neutrophilia, prevalence of diabetes, 151 ulcerative and Crohn's disease, and medication use compared to the non-carriers. Sensitivity analyses 152 performed using partial Spearman correlation showed loss-of-significance for 32 species. However, 153 extensive sensitivity analyses did not find any evidence for this difference resulting from single 154 influential observations nor non-linear effects, and differences were thereby likely to be due to lower 155 power compared to linear model (Supplementary Information, Supplementary Table 6 and 7). 156 157 Even if not directly indicated as confounders, we further assessed the effect of adjustment for BMI and 158 proton-pump inhibitors (PPI) medication, as well as excluding specific groups of individuals such as those with Crohn's disease or those with antibiotic treatment the past 12 months from the analyses. 159 160 We also tested the effect of not adjusting the basic and full models for Shannon diversity index to 161 observe if some of these factors could explain the identified associations of the species and CACS 162 (extensively explained in Supplementary Information, Extended Data Fig. 4, Supplementary 163 Table 6 and 7). Statistical significance was lost for a few species in some of the analyses; however, 164 effect estimates remained largely similar. Overall, these findings indicate that the associations 165 identified in the main analysis were robust and were not in general affected by statistical model 166 misspecification, PPI or antibiotic use, or gastrointestinal disease. Moreover, our findings show that the identified species are in general associated with CACS independent of established cardiovascular 167 risk factors. 168

169 Sex modifies the association between certain species and subclinical atherosclerosis. We re-

assessed the 63 species associated with CACS in the full model stratifying for sex, and tested whether

171 the effect estimates in the female strata were different to the male strata (Extended Data Fig. 5,

172 Supplementary Tables 3 and 8). *Streptococcus agalactiae*, *Rothia mucilaginosa*, and two

173 *Eubacteriales* spp. (HG3A.0242 and HG3A.0854) showed different effect estimates across sex

174 (Cochran's Q-test p-value<0.05) where the two first mentioned species were associated in females only

and the two latter in males only. These findings indicate that sex-specific associations are present

176 between gut microbiota and subclinical coronary atherosclerosis.

177 Few CACS-related species are also associated with carotid atherosclerosis. Next, using ordinal

178 regression analysis with basic model adjustment and a FDR of 5%, we searched for associations of

179 CACS-associated species with carotid atherosclerosis in 8,955 SCAPIS participants with available

180 information of carotid atherosclerosis measured with ultrasound, in addition to deep shotgun

181 metagenomics and CACS (Supplementary Table 9). Subjects were categorized as "no identified

atherosclerosis" (n=3,821), "atherosclerosis in one carotid artery" (n=2,779), and "atherosclerosis in

both arteries" (n=2,355). Carotid atherosclerosis was detectable in 57% of the SCAPIS participants

184 which is higher than in previous large-cohort studies: 34% in the Atherosclerosis Risk in Communities

study (ARIC)²⁰, 47% in the Multi-Ethnic Study of Atherosclerosis (MESA)²¹, 44% in the Malmö Diet

and Cancer study (MDC)²², and 45% in Risk Evaluation For INfarct Estimates (REFINE)-Reykjavik

187 study²³. Twenty-one of the CACS-related species were associated with carotid atherosclerosis in the

188 basic model including *Streptococcus mutans*. However, *Blautia obeum*, *Clostridium phoceensis*,

189 *Oscillibacter* sp. (HG3A.0243), *Intestinimonas* sp. (HG3A.1018) and three *Eubacteriales* spp.

190 (HG3A.0242, HG3A.0511, HG3A.1158) remained significant in the ordinal regression with the full

191 model adjustment (Supplementary Table 9). These results may suggest that gut microbiota

associations differ between the two vascular beds; however, it might also depend on differences in themeasurement methods.

Fifteen CACS-related species, including seven *Streptococcus* spp., are validated using a case control study of symptomatic atherosclerotic cardiovascular patients. We next attempted to

replicate findings using shotgun metagenomics data from a case-control study¹³ of 210 patients with 196 197 symptomatic ACVD and 163 controls from a Chinese population representing a later stage of the 198 atherosclerotic process, wider age range (32-107 years), different genetic background and geographical area, and also likely different dietary habits and medication usage, which are all factors 199 that can modulate gut microbiota composition. Of the 73 species associated with CACS in the basic 200 model in the current study, we could identify 64 species using the same gene sequence signatures as in 201 202 the SCAPIS study. Fifteen of these 64 species, including seven Streptococcus spp. were associated 203 with ACVD with consistent effect direction as in SCAPIS using logistic regression models adjusted 204 for age, sex and Shannon diversity index at an FDR of 5%, where disease status was the dependent variable and the rank-base inverse transformation of the relative abundance was set as the independent 205 206 variable of interest (Extended Data Fig. 6 and Supplementary Table 10). 207 Trehalose and fructose degradation genes are enriched in CACS-related species, especially in 208 Streptococcus genus. Next, to identify possible bacterial functions that might be involved in the 209 coronary subclinical atherosclerosis and shared between the associated bacteria, we used GSEA to identify functional gut metabolic modules (GMM)²⁴ enriched for the CACS-associated species. The 210 211 GSEA were based on ranked p-values from the basic association model with CACS stratified by the direction of the regression coefficient. The analysis revealed four enriched functional GMM in the 212 bacterial species positively associated with CACS, and one enrichment in species negatively 213 214 associated with CACS (Extended Data Fig. 7a, b and Supplementary Table 11 and 12). The 215 positive enriched modules were involved in amino acid degradation (threonine degradation I and II) 216 and carbohydrate degradation (trehalose degradation and fructose degradation), while the negative 217 module was involved in acetogenesis. To test if these functions were enriched due to the overrepresentation of Streptococcus spp. associated with CACS, we performed GSEA applying leave-218 219 one (taxon)-out analysis (Extended Data Fig. 7c, Supplementary Table 13 and 14). This analysis revealed that the trehalose and fructose degradation functions were strongly attenuated when we 220 221 removed *Streptococcus* spp., and to a lesser extent the threonine degradation II, supporting that 222 *Streptococcus* spp. are important contributors for the association of these functions with CACS.

223 Streptococcus spp. have a high ability to catalyze different types of carbohydrates including most common dietary sugars (fructose, glucose and sucrose) forming compounds involved in virulence 224 processes including biofilm buildup²⁵. Trehalose degradation has been linked to virulence, and its role 225 as a stress protectant has been linked to protection from desiccation freezing, starvation, and osmotic 226 227 stress^{26,27}. For threonine degradation I, *Roseburia* was the important genus, for threonine degradation II, Bifidobacterium, and for homoacetogenesis, Romboutsia. Together, these results show that CACS-228 229 associated species share, at least partially, some specific bacterial functions related to amino acid and 230 carbohydrate degradation, and that Streptococcus spp. were the most important contributor to the 231 enrichment for trehalose degradation genes, a function previously linked to bacterial virulence. Plasma bile acids, androgenic steroids, and sphingomyelin-associations with CACS-associated 232 Streptococcus spp. are overrepresented. Next, we identified 2,377 associations between seven 233 CACS-associated Streptococcus spp., and 873 of the 1,412 plasma metabolites detected in 7,252 234 SCAPIS participants using partial Spearman correlation adjusted at 5% FDR (Extended Data Fig. 8 235 236 and **Supplementary Table 15**). Among the positive associations, primary bile acid metabolism was 237 enriched in four Streptococcus spp. (S. gordonii, S. parasanguinis, S. salivarius, and S. oralis. subsp. oralis), while secondary bile acid metabolism, acetylated peptides, and analgesics and anesthetics 238 239 drugs sub-pathway were enriched in S. anginosus; and plasmalogen in S. oralis subsp. oralis (Fig. 3a 240 and Supplementary Table 16). At individual metabolite level, all 11 primary bile acid metabolites 241 were positively associated with all the Streptococcus spp. with adjusted p-values<0.05, with the 242 exception of chenodeoxycholic acid sulfate. We further observed that metabolites from analgesic and 243 anesthetic medications were positively associated with all the *Streptococcus* spp., particularly those 244 metabolites derived from paracetamol. Furthermore, omeprazole was strongly associated with the Streptococcus spp., with the exception of S. agalactiae. In contrast, androgenic steroids metabolites 245 246 and sphingomyelins showed enrichment among the metabolites negatively correlated with S. gordonii, S. parasanguinis, S. salivarius, and S. mutans; and S. mutans and S. anginosus respectively (Figure 3a 247 248 and Supplementary Table 17). Notably, all androgenic steroids and 26 of the 29 sphingomyelins 249 metabolites were negatively associated with CACS-related Streptococcus spp. with adjusted p-

values<0.05. For androgenic steroids, sex-differences in the effect estimates were tested. Eleven 250 metabolites reported different effect estimates across sex (Cochran's Q-test p-value<0.05). 251 Collectively, these results show the tight relationship between CACS-associated Streptococcus spp. 252 253 and endogenous and exogenous metabolites. Next, we additionally adjusted the full model assessing the relationship between Streptococcus spp. and CACS for the Streptococcus-associated metabolites 254 (with <30% missing data) involved in sub-pathways related to primary and secondary bile acids 255 256 metabolism, acetylated peptides, plasmalogen, androgenic steroids, sphingomyelins, analgesic and 257 anesthetic drugs, and/or partially characterized molecules to assess the potential mediation by these 258 metabolites (Extended Data Fig. 9 and Supplementary Table 18). The inclusion of these metabolites in the models did not attenuate the association between *Streptococcus* spp. and CACS compared with 259 260 the full model restricted to complete data (n=5,683), indicating that the association is not mediated by 261 these metabolites (Extended data Fig. 9).

Streptococcus spp. are associated with markers of systemic inflammation and infection. To test 262 263 whether Streptococcus spp. were associated with markers of systemic inflammation and infection, respectively, we evaluated the associations between these species and high-sensitivity plasma C-264 265 reactive protein (hsCRP) (n=7,248), and counts of leukocytes (n=7,237) and neutrophils (n=7,235). 266 Five out of seven CACS-associated Streptococcus spp. (S. anginosus, S. parasanguinis, S. oralis subsp. oralis, S. gordonii and S. salivarius) were positively associated with hsCRP and leukocyte 267 268 counts. The same five Streptococcus spp. and S. mutans were positively associated with neutrophil 269 counts (Fig. 3b and Supplementary Table 19). These models were adjusted for age, sex, country of 270 birth, smoking, physical activity, fiber and total energy intake, and self-reported medication for 271 dyslipidemia, hypertension and/or diabetes, Shannon diversity index, center site and extraction plate. The inclusion of BMI and PPI into the models attenuated the estimates but all five species remained 272 273 associated with hsCRP, while only S. parasanguinis and S. salivarius remained associated with 274 leukocytes and neutrophils counts. S. oralis subsp. oralis was also associated with neutrophils counts 275 (Supplementary Table 20).

Overall, these findings suggest that these *Streptococcus* spp. are related to markers of inflammation
and infection, which have been described as plausible mechanisms in gut microbiota effects on the
atherosclerosis process².

279 Gut Streptococcus spp. are correlated with oral Streptococcus spp. and the latter are associated with oral health. Streptococcus spp. are commonly localized in the oral cavity and are linked to worse 280 oral health status. We investigated the correlation between the abundance of CACS-related 281 Streptococcus spp. in the fecal and saliva samples from 343 participants in the Malmö Offspring 282 283 Dental Study (MODS) with an age range between 23 and 71 years who underwent a thorough dental examination within 4 to 12 months after fecal sampling in the Malmö Offspring Study (MOS)²⁸. The 284 gene signature in the saliva samples mapped to S. anginosus, S. parasanguinis, S. gordonii, S. mutans, 285 S. oralis, and two different S. salivarius (Ho1B.0002 and Ho1B.0234) in the catalogue. Unfortunately, 286 287 we could not identify S. agalactiae in the salvia samples. We applied partial Spearman correlations 288 with cluster-robust standard errors accounting for relatedness between the CACS-related Streptococcus spp. in the gut and the corresponding species in the oral cavity adjusting for age, sex, 289 290 country of birth, and extraction plate of the fecal samples. Five Streptococcus spp. (S. anginosus, S. 291 parasanguinis, S. gordonii, S. mutans and S. salivarius) from the fecal samples were positively 292 associated with their homologous species in the oral cavity (rho=0.15-0.30) (Supplementary Table 293 21). To investigate whether the oral *Streptococcus* spp. corresponding to CACS-associated gut 294 bacteria species were associated with oral health, we fitted a series of ordinal regressions with cluster-295 robust standard errors with three different outcomes (filled surfaces, surfaces with caries (initial and 296 manifest), or gingival inflammation in 637 participants from MODS. These models were adjusted for 297 age, sex, smoking, education, oral hygiene, activity realized the hour before the dental examination 298 including eating, brushing teeth or/and smoking, and Shannon diversity index (Extended data Fig. 299 10). S. anginosus was associated with all three outcomes at 5% FDR. S. mutans was associated with 300 gingival inflammation and caries. S. parasanguinis and S. salivarius were associated with filled surfaces while S. gordonii was associated with gingival inflammation (Fig. 3c and Supplementary 301 302 Table 22). Further adjustments for BMI, PPI and antibiotic treatment provided similar estimated

effects, indicating that these associations are independent of these factors (Supplementary Table 23).
These findings showed a correlation between oral and gut microbiota, which may explain a migration
of these species from the oral cavity to the gut. Furthermore, we observed four *Streptococcus* spp.
associated with oral health, which may contribute to mechanisms underpinning the association
between oral health and atherosclerosis process.

308 Discussion

Gut bacteria have been proposed to affect atherosclerosis progression and development through 309 310 infections local or distal to the atherosclerotic plaque, or through production of metabolites affecting the atherosclerotic process^{2,29}. The association of gut microbiota with coronary atherosclerosis has 311 previously only been studied in symptomatic patients, who are often under treatment, resulting in high 312 risk of bias. To address the previous biased sampling, we leveraged the large population-based 313 314 SCAPIS cohort with detailed image-based measurements of coronary artery atherosclerosis, and deep characterization of the gut microbiome using shotgun metagenomics. We identified 73 species 315 associated with CACS, with an enrichment of *Streptococcus* spp. and gene functions involved in 316 317 amino acid and carbohydrate degradation. Our findings further supported that gut Streptococcus spp. 318 were independently associated with endogenous and exogenous plasma metabolites, with 319 inflammatory and infection markers, and with their bacterial homologues in the oral cavity, which 320 were associated with worse oral health. Together, these findings provide robust evidence of the association of Streptococcus spp., with subclinical atherosclerosis and markers of systemic 321 322 inflammation and infection, calling for studies to re-investigate the role of bacteria in atherosclerosis 323 pathogenesis.

The *Streptococcus* genus was clearly enriched in the associations between species and CACS, in line with observations in earlier ACVD case-control studies^{7,13,14}. Specifically, we observed *S. anginosus*, *S. oralis* subsp. *oralis*, *S. parasanguinis*, *S. gordonii*, *S. salivarius*, *S. mutans*, and *S. agalactiae* associated with increased CACS. These species commonly colonize the oropharyngeal cavity and the digestive tract³⁰ and all belong to the viridans streptococci group (VGS), except for *S. agalactiae* that

329 is a β -hemolytic non-VGS. An overview of the current knowledge of the involvement of these specific bacteria in cardiovascular pathologies is provided in Supplementary Table 24. VGS has the ability to 330 331 infect the valves and the coronary vessels accounting for 20% of infective endocarditis cases, and they have been isolated from human coronary atherosclerotic plaque samples from coronary artery disease 332 patients^{31–33}. Some studies on animal models support a causal link between *Streptococcus* species and 333 the atherosclerotic process 3,34,35 . For instance, atherosclerosis-prone mice orally challenged with S. 334 sanginius had pro-inflammatory responses in the aorta, and accelerated atherosclerosis³. In the present 335 336 study, we observed strong positive associations between abundance of CACS-associated 337 Streptococcus species in the gut and hsCRP, leukocytosis and neutrophilia, which could have been triggered by low-grade bacteremia. Among patients with bacteremia, VGS is a common cause^{36,37}. 338 339 VGS species are early colonizers, and may contribute to or initiate biofilm formations. Biofilms are syntrophic beneficial poly-microbial communities that facilitate bacterial survival in aerobic 340 environments such as the atherosclerotic plaque³⁸ and biofilms have been observed in atherosclerotic 341 lesions associated with the fibrous cap³⁹, however causal relationships are not clear. Both biofilms and 342 343 VSG can induce persistent inflammation, attract monocytes into the endothelial space, and contribute to platelet aggregation, all of which are the requisites for promoting the atherosclerosis 344 development^{40,41}. Both local and distal infections require translocation of bacterial species to the 345 346 bloodstream. In the oral cavity, VGS form biofilms on the tooth surface and they can enter to the 347 bloodstream following mucosal barrier injuries, for example daily dental care activities, invasive dental procedures, and oral pathologies, which have been associated with increased risk of 348 atherosclerosis, myocardial infarction, and stroke⁴²⁻⁴⁸. Our results indicated associations between the 349 oral VGS and worse oral health, which can potentially be the entry point to the bloodstream. 350 351 A potential modifier of *Streptococcus* spp. abundance would be antimicrobial treatment. However, 352 multiple clinical trials have demonstrated inefficacy of anti-infective therapies in mitigating atherosclerotic cardiovascular events⁴⁹. The CLARICOR study⁵⁰, in which patients with stable 353 coronary artery disease were treated with clarithromycin, an antibiotic that can be used to treat 354 Streptococcus spp. infections, reported increased mortality in the treatment arm. One possible 355

explanation for this lack of efficacy even though *Streptococcus* spp. would be causally related to
atherosclerosis, could be the formation of *Streptococcus*-associated biofilms that increase the bacterial
resistance to antibiotic treatment up to 1,000 times⁵¹, or alternatively, antibiotic treatment could lead to
a recolonization of more pathogenic bacteria. Furthermore, the treatment window could exist much
earlier in the atherosclerosis process. In the current study, the association between the *Streptococcus*spp. and calcification in the coronary arteries remained after exclusion of those participants treated
with antibiotics the past year.

363 Additionally, gut microbiota composition could affect atherosclerosis development through effecting 364 the host metabolism. We identified 1,412 associations between CACS-associated Streptococcus species in the gut and plasma metabolites, with an overrepresentation of associations with plasma bile 365 acids, androgenic steroids, and sphingomyelins. Gut microbiota species are essential to transform 366 367 primary bile acids to secondary bile acids that enter circulation and interact with host bile acid receptors. Knock-out mice of these receptors were shown to be protected against atherosclerosis 368 development or progression⁵². Elevated plasma bile acids have also previously been associated with 369 increased risk of coronary plaques in asymptomatic individuals⁵³. However, other studies have 370 reported a null or a protective role in symptomatic disease^{54,55}. 371

372 *Streptococcus* spp. were also inversely associated with androgenic steroids and sphingomyelins.

373 Androgenic steroids, which have a similar structure to bile acids, are recycled through enterohepatic

374 circulation, which is partially regulated by gut microbiota⁵⁶. Low levels of dehydroepiandrosterone

375 (DHEA) have previously reported to associate with an increased risk of death caused by CVD in

elderly men⁵⁷. The role of sphingomyelins in the cardiovascular outcomes remains controversial. Some

377 studies reported higher levels of sphingomyelin in coronary heart disease (CHD) patients compared to

378 controls and these elevated levels were associated with earlier subclinical atherosclerosis 58-61.

379 However, other studies suggest that long-chain saturated sphingomyelins may protect from CHD

incidence⁶², while follow-up studies indicated no association between plasma sphingomyelins and

incidence of CHD^{63} . Collectively, these observations show that *Streptococcus* spp. are correlated with

382 many metabolites that were suggested in previous studies to be related to CVD.

There are some limitations in the current study. First, few participants presented high levels of 383 subclinical atherosclerosis, and thus limiting statistical power, which was however counteracted by the 384 385 size of the cohort analyzed that represents a population at least seven times larger than those analyzed previously. Second, microbial composition can vary extensively throughout the gastrointestinal tract 386 and quantification of the microbial communities in fecal samples represents the microbial population 387 at the distal colon, but does not comprise other sites⁶⁴ such as the small intestine, meaning that our 388 389 study design might not allow discovery of species that are underrepresented in fecal samples. Third, 390 we were unable to validate 64% of our findings in the discovery in the validation attempt. Here a more 391 similar study of larger size would have been useful. As the validation was performed in a small casecontrol study of symptomatic disease, we could not determine whether the lack of replication for some 392 393 of our findings was caused by lack of true association, lack of power, differences in study design, and/or due to cross-country differences. Fourth, our study does not take into consideration the different 394 interactions among bacterial species such as synergistic effects in the relationship with coronary 395 396 atherosclerosis. Finally, the cross-sectional study design prevented causal inferences. Different causal 397 inference methods could be used in future studies to disentangle the underlying relationships and determine whether the identified species and suggested mediators are causally related to 398 atherosclerosis development. 399

400 In conclusion, by combining data from a large population-based cohort study and highly accurate

401 bioimaging to evaluate subclinical coronary atherosclerosis, we identified seven *Streptococcus* spp.

402 associated with CACS, biomarkers of inflammation, and with their oral counterparts. These

403 *Streptococcus* spp. may affect the atherosclerosis plaque development by direct infection or alteration
 404 of host metabolism. Future studies investigating the causal relationship in these associations will show

405 whether these species can be used as potential biomarkers or treatment targets.

406 **Online Methods**

407 Study design and participants. SCAPIS was used as the primary data source. SCAPIS is a national
408 Swedish general population study including 30,000 subjects aged 50–64 years, at six study sites,

409 focusing on phenotypes relevant to CVD, chronic obstructive pulmonary disease, and related metabolic disorders¹⁸. Participants from the Uppsala (n=4,541) and Malmö (n=4,432) centers were 410 411 included in the present study after excluding 846 participants with prevalent CVD (self-reported myocardial infarction, angina, atrial fibrillation, heart valve disease, previous bypass surgery or 412 percutaneous coronary intervention, revascularization of other arterial vessel, and stroke) before the 413 baseline visit or missing information on country of birth or CACS. All participants gave written 414 415 informed consent before participation. This investigation followed the principles expressed in the 416 Declaration of Helsinki and was approved by the Swedish Ethical Review Authority 417 (Etikprövningsmyndigheten Dnr 2010-228-31M, Dnr. 2018/315). The results were validated in a published case-control study¹³ of 214 cases and 171 controls of Han 418 419 Chinese origin. The phenotypic data for the validation study are publicly available through the curatedMetagenomicData R package⁶⁵. In this study, patients and controls aged 40–107 were recruited 420 421 at the Medical Research Center of Guangdong General Hospital. Cases showed clinical manifestations of stable angina, unstable angina, or acute myocardial infarction. The diagnosis was confirmed by 422 coronary angiography, and individuals with \geq 50% stenosis in a single or multiple vessels were 423 424 included in the study. At the time of medical examination, controls were free of any clinical symptom 425 of ACVD including peripheral artery disease (coronary artery disease or myocardial infarction), cardiomyopathy, renal failure, peripheral neuropathy, systemic disease, and/or stroke¹³. 426 427 We investigated the association between *Streptococcus* spp. located in the gut and in the oral cavity in 428 the MODS, a sub-study of MOS. MOS was performed in 2013-2021 including 5,259 adults (18-71 429 years old), which consisted of children and grandchildren from participants examined at the baseline (1992–1996) of the Malmö Diet Cancer Study Cardiovascular Arm, and it aimed to identify gene-430 431 environment interactions of major diseases. The attendance rate of MOS was 47.9% and details of the study can be found in Brunkwall et al.⁶⁶. Participants attending MOS 2014–2018 were eligible to 432 participate in MODS (n=2,643) after the second visit in MOS. In total 831 individuals were recruited 433 in MODS. The participants underwent a thorough dental examination including clinical examination, 434 panoramic and bite-wing radiography. The Malmö Offspring Dental Study (MODS) was approved by 435

the Regional Ethics committee (Regionala etikprövningsnämden, REPN) in Lund (Dnr 2013/761),
which is part of the Malmö Offspring Study (MOS) with ethical approval from Regional Ethics
committee (REPN) in Lund (Dnr 2012/594).

439 CACS determination. The total calcium score was measured in SCAPIS participants by summing the 440 CACS in the left main coronary artery, anterior descending artery, circumflex artery, and right coronary artery. The specific methods for this measurement are available in Bergström et al.¹⁸. 441 442 Carotid plaque assessment. The numbers of plaques in the left and right carotid arteries were 443 determined in SCAPIS participants from two-dimensional grey-scale ultrasound images obtained using a standardized protocol with a Siemens Acuson S2000 ultrasound scanner equipped with a 9L4 444 linear transducer (both from Siemens, Germany) following the Mannheim consensus⁶⁷. Carotid plaque 445 presence was categorized in three categories. None: absence of identified plaques in both vessels; 446

unilateral: identified plaques in one of the two vessels; and bilateral: identified plaques in both
vessels¹⁸.

449 Inflammation and infection markers. Clinical chemistry, including hsCRP, was carried out on
450 venous blood from SCAPIS participants. A blood cell count, including white blood cell differential,
451 was also performed.

452 **Oral health phenotypes.** Five trained dentists performed the dental examination in MODS

453 participants. Caries was detected using standard clinical criteria aided by mirror, probe (Hu-Friedy

454 EXD57), and bite-wing radiographs. Cavitated lesions that extend into the dentin were recorded as

455 manifest caries and a primary lesion not reaching the stage of manifest as initial. Initial and manifest

456 lesions were summed for a combined variable of surfaces with caries. Filled surfaces included both

457 fillings and crowns. Both caries and fillings were recorded on all teeth, counting five surfaces.

458 Gingival inflammation was recorded as percentage of bleeding on probing excluding wisdom teeth

and counting on six surfaces per tooth using a Hu-Friedy PCPUNC157 probe.

460 Other phenotypes. In SCAPIS the sociodemographic, lifestyle, health, and cardiovascular risk factor
 461 information were collected using validated and standardized questionnaires¹⁸. Self-reported

cardiovascular, Crohn's, and ulcerative diseases, as well as self-reported medication for high blood 462 pressure, dyslipidemia, and diabetes were categorized as binary variables. The recruitment center was 463 464 also categorized as a binary variable (Malmö or Uppsala). Self-reported smoking was categorized as 465 never, former, and current smoker. The participants were grouped into sedentary, moderate exercise, moderate but regular exercise, and regular exercise and training in leisure time categories according to 466 467 self-reported physical activity. The participants' country of birth was categorized as Scandinavia, 468 Europe, Asia, and other. The Scandinavia group included participants who were born in Sweden, 469 Denmark, Norway, or Finland. BMI was determined by dividing the weight (measured in kg) by the 470 square of the height (measured in meters). The participants who received PPI drugs were classified into a binary category, using plasma metabolomics information. The participants who had measurable 471 472 omeprazole and/or pantoprazole levels in the plasma over the detection limit were classified as PPI 473 drug users. Total energy intake and fiber intake were derived from the food frequency questionnaire. 474 Both variables were natural log-transformed. Participants who reported values of ln(total energy 475 intake) over or below the geometric mean of $\ln(\text{total energy intake}) \pm 3$ standard deviations in the 476 population were excluded. Linkage with the drug prescription register was performed for antibiotic drug use (Anatomical Therapeutical Chemical code J01). Those participants who received a 477 prescription for these drugs during the year preceding their attendance of the baseline visit were 478 479 classified as participants with antibiotic drug treatment.

In the validation case-control study¹³, the sociodemographic information was collected using
questionnaires. No information on Crohn's and ulcerative diseases, cardiovascular medication, and
physical activity was available. Smoking exposure was available only for 8.8% of the participants and
none of them were under antibiotic treatment.

In the MOS population, the sociodemographic, lifestyle, and medication treatment were collected using validated and standardized questionnaires. Country of birth was categorized in two levels (Sweden or other) and self-reported information of the PPI was used. BMI was measured dividing the weight (measured in kg) by the square of the height (measured in meters). Participants belonging to the same family were registered in a variable called "family id". For the participants included in

MODS, we obtained information using standardized questionnaires filled out during the dental 489 examination. Smoking was categorized as never, former and current smoker. The participants were 490 491 grouped in primary education, secondary education or university degree according to the level of education acquired. Self-reported information of the antibiotic usage was categorized as binary 492 493 variable depending on if the participants received antibiotic treatment the last three months. The 494 activity performed by the participant during the previous hour before attending the dental examination 495 included three variables categorized as binary depending on whether the participant did or did not the 496 following actions: eat, smoke, and/or brush their teeth. The oral hygiene was assessed using the Löe plaque index and the mean degree of plaque per tooth surface was calculated⁶⁸. Therefore, we summed 497 the number of surfaces with plaques identified during the dental exploration divided by the number of 498 499 teeth multiplied by six surfaces.

500 Metagenomics. General considerations. For SCAPIS-Malmö and MOS samples, the whole analytical 501 process was performed together in the project "lungut", from DNA extraction to relative abundance calculation for each identified species, at Clinical Microbiomics A/S (Copenhagen, Denmark), 502 following standardized methodology. The samples from lungut and SCAPIS-Uppsala were 503 504 randomized on box-level (16 samples per box) and all the samples from these three studies were processed together during the years 2019 and 2020. MODS saliva samples were also carried out in the 505 506 same company following the same pipeline during the year 2020, but it was not processed together 507 with the three other studies. For the validation study¹³, the analytical pipeline for the metagenomics 508 analysis from the FASTQ files to the relative abundance calculation for each identified species was 509 also performed in Clinical Microbiomics A/S (Copenhagen, Denmark).

510 Handling and analyses of SCAPIS, MOS and MODS. Clinical Microbiomics A/S (Copenhagen,

511 Denmark) processed three different projects that were: lungut (fecal samples from SCAPIS-Malmö

and MOS samples), SCAPIS-Uppsala (fecal samples) and MODS (saliva samples). For lungut and

513 SCAPIS-Uppsala, DNA was extracted from fecal samples using NucleoSpin® 96 Soil (Macherey-

514 Nagel, Germany) from the same batch (Lot: 1903/001) to limit the technical bias. For MODS, DNA

515 was extracted from 250 µL saliva using the same tools. At least one negative control (no sample

material) was included per batch of sample during the extraction process. One positive control (mock) 516 was included per batch during the whole laboratory process for all the projects, including DNA 517 518 sequencing. DNA extraction quality was evaluated using agarose gel electrophoresis and the quantity 519 was determined by Qubit 2.0 fluorometer for the three projects. The genomic DNA was randomly sheared into fragments of approximately 350 bp. The fragmented DNA was used for library 520 construction using NEBNext® Ultra Library Prep Kit for Illumina (New England Biolabs, MA, USA). 521 522 The sample index pairs were unique for each sample per run. The prepared DNA libraries were 523 purified using AMPure XP kit, and evaluated using Agilent 2100 Bioanalyzer to determine fragment size distribution. Before sequencing, the concentration of the final libraries were determined using 524 525 quantitative real-time PCR. The libraries were sequenced using an Illumina Novaseq 6000 instrument using 2×150 bp paired-end reads. The sequencing process generated on average 26.3 million read pairs 526 527 per sample in lungut, 25.3 million read pairs in SCAPIS-Uppsala and 26.3 million read pairs in 528 MODS. Reads with >10% ambiguous bases, or >50% bases with Phred score (Qscore) <5 were removed. On average, 97.9% of the sequenced bases had a Oscore >20 in lungut, 97.8% in SCAPIS-529 Uppsala and 97.4% in MODS. Reads that mapped the human reference genome GRCh38 using 530 Bowtie 2 v.02.3.4.1⁶⁹ (selecting default settings) were removed from FASTO files. The remaining 531 532 reads, classified as high-quality non-host reads (NQNH), were mapped to the gene catalog using BWA 533 mem v.0.7.16a. The reads were considered mapped if the following criteria were met: an alignment of \geq 100 bases, \geq 95% identity in this alignment, mapping quality (MAPQ) \geq 20, and \leq 10 bases failing to 534 align with the gene sequence at either end. Reads meeting previous criteria except the MAPQ 535 threshold were considered multi-mapped. A gene count table was created with the number of mapped 536 read pairs for each gene. Two specific gene catalogues were built. The first catalogue was built for the 537 538 fecal samples including 6,813 samples from lungut, 4,876 from SCAPIS-Uppsala, 9,428 from Pasolli et al.⁷⁰, and 3,486 publicly available genome assemblies for isolated microbial strains, selected for 539 540 their relevance or potential relevance to the human gut or because they are used in commercially 541 available mock microbial communities. The second catalogue was built for the saliva samples 542 including 706 MODS samples, 1,305 oral samples compiled from 21 publicly available data sets, and 543 1,326 publicly available genome assemblies from isolated microbial strains, selected for their

relevance or potential relevance to the human mouth, and 81 genome assemblies corresponding to 544 545 commercially available mock microbial communities. The HQNH reads from the samples were assembled using MEGAHIT $(v.1.1.1)^{71,72}$ into contigs of >500 bp. The contigs from lungut, SCAPIS-546 Uppsala, Pasolli et al.⁷⁰, and genome assemblies were combined, and genes were predicted using 547 Prodigal Gene Prediction Software (v.2.6.3, metagenomics/anonymous mode; ; 548 549 https://github.com/hyattpd/Prodigal). The contigs from MODS were combined with genome 550 assemblies and genes were predicted using the same software. Genes and partial genes with a length <102 bp were removed, resulting in a set of 2.95×10^9 genes in the human gut catalogue and 1.89×10^8 551 552 genes in the human oral catalogue. For the human gut catalogue, the gene sequences were clustered using MMseqs2 (Release 11)⁷³ ("pre-clustered" at 98% identity over 95% coverage of the longer 553 sequence (>3 kbp), followed by 93% identity over 70% coverage of the shorter sequence (\leq 3 kbp)). 554 555 For each cluster, a representative sequence was chosen based on the following criteria: first prioritize sequences derived from metagenome assembly (lungut, SCAPIS-Uppsala and Pasolli⁷⁰) over those 556 derived from isolated strain (genomes); then prioritize sequences representing the largest (cardinality) 557 pre-cluster; then prioritize the longest sequence. The two sets of representative sequences were then 558 re-clustered using the same criteria. The resulting sets of short and long cluster representatives were 559 combined as follows: 1) All short cluster representatives were compared to all long cluster 560 561 representatives and all alignments at 93% identity over 70% coverage of the shorter sequence were identified. 2) All genes that did not have an alignment were retained. 3) For genes that did have an 562 alignment, the short gene but not the long gene were retained. The resulting set of 33.5 million 563 564 sequences was then filtered to retain only sequences that represent a cluster with ≥ 1 reference-derived sequence and/or \geq 5 metagenome-derived sequences, or must have been specifically selected for its 565 566 relevance, e.g. as a pathogen or as a component of a mock community to build a non-redundant human 567 gut gene catalog (version "HG3A") of 14,147,921 microbial genes. For the human oral catalogue, the gene sequences were clustered using MMseqs2 (Release 11)⁷³ ("pre-clustered" at 93% identity over 568 70% coverage of the longer sequence, followed by 93% identity over 70% coverage of the shorter 569 sequence). We searched for alignments between long gene cluster representatives and short gene 570 cluster representatives at 93 % identity over 70 % coverage of the shorter sequence; for all matches we 571

removed the long gene and retained the short gene. The merged long and short genes were filtered to
remove sequences with tetramer entropy below 4, resulting in a non-redundant human oral gene
catalog (version "Ho01") of 8,554,253 microbial genes.

575 Metagenomic species (MGS) core gene sets were defined as bins of co-abundant genes identified using gene abundances from the correspondent non-redundant gene catalog across the cohorts that 576 passed the quality assessment according to Nielsen et al.⁷⁴. Species abundance was estimated 577 578 according to the signature gene set, which was assigned using 100 genes with the highest correlation 579 to the median core gene abundance for each species. A table of species counts taking into account the total gene counts for the signature gene per species was created. A metagenomics species was 580 considered detected if the read pairs were mapped to least three of the 100 signature genes. Species 581 that did not fulfill this criterion were set to 0, resulting in a 99.6% of specificity, according to the 582 583 internal benchmarks. The species count table was normalized for effective gene length (accounting for 584 the read length). The relative abundance of each species was estimated normalizing it to the sum 585 (100%). All analyses were performed at the species level.

For beta diversity analyses and the comparison of carriers and non-carriers between the two center sites, downsized MGS relative abundance data was used. The estimation of downsized MGS was performed by random sampling without replacement from the gene count table corresponding to the signature genes. Both lungut and SCAPIS-Uppsala were downsized to 210,430 reads. One sample from SCAPIS-Uppsala was discarded due to it presented only 1,473 reads mapped to the signature genes and downsizing all the samples to 1,473 reds would result in a huge loss of precision.

The taxonomical information was annotated after comparing all the genes on the two catalogues with
 NCBI RefSeq database⁷⁵ for archaea, bacterial, fungal, protozoa, and viral genomes, using BLAST

algorithms. Human gut catalogue was compared with NCBI RefSeq downloaded on 02 May 2021 and

the human oral catalogue was compared with the version downloaded on 27 January 2020. To

annotate at the various taxonomic ranks, we required different levels of identity (95%, 95%, 85%,

597 75%, 65%, 55%, 50% and 45% for subspecies, species, genus, family, order, class, phylum, and

superkingdom, respectively) and a minimum of 80 % sequence coverage. If >75% of the MGS genes

599 mapped to a single species the MGS was annotated to this species. For genus, family, order, class and 600 phylum the thresholds were set to 60%, 50%, 40%, 30% and 25% respectively. Furthermore, at genus 601 and species level the MGS was not annotated to this level if >10% of the genes mapped an alternative 602 species or genus.

603 The functional annotation was performed by comparing each gene in the catalog to the EggNOG (v. 5.0)⁷⁶ orthologous groups database (http://eggnogdb.embl.de/) using EggNOG-mapper software (v. 604 605 $(2.0.1)^{77}$. This comparison provided annotation to the Kyoto Encyclopedia of Genes and Genomes 606 (KEGG) orthology (KO) database (https://www.genome.jp/kegg/). The functional potential profile was determined with GMM²⁴, which includes 103 metabolic pathways that represent a cellular 607 enzymatic process. MGS were assigned to a GMM if they contained at least two-thirds of the KOs 608 609 required for the functionality of the module. If the module consisted of three or fewer steps, the MGS 610 must contain all the steps. If the module contains alternative paths, the MGS only have to contain one of the paths. 611

For lungut, SCAPIS-Uppsala and MODS, no detectable levels of DNA were observed for negative

613 controls, while detectable levels of DNA were observed for mock samples. The mock samples showed

a coefficient of variation estimated by the Shannon diversity index of 3.30% in lungut and 3.05% in

615 SCAPIS-Uppsala. The coefficient of variation for 158 pairs of biological replicates randomly

616 introduced in the analysis in SCAPIS-Uppsala center (where Clinical Microbiomics was blind to this

617 information) was 1.49%.

618 *Analyses of the validation study.* All the FASTQ files from the validation study were directly

619 downloaded from the European Nucleotide Archive (ENA) under the project code "PRJEB21528".

620 The bioinformatics processing of reads, mapping to the catalogue, MGS count table generation and

621 MGS relative abundance calculation steps were performed following the same algorithm used in the

622 SCAPIS and MOS samples, with the exception of a minimum read-to-gene alignment length >90 bp to

accommodate the 2X100 paired-end sequencing in the validation study.

Metabolomics data. Fasting plasma samples were stored at -80 °C until they were processed by 624 Metabolon Inc (Durham, NC, USA), as described by Evans et al.⁷⁸. The order of the SCAPIS samples 625 626 were randomized and they were analyzed together with quality control standards including pure water. 627 solvents used for metabolite extraction and a pool of human samples maintained by Metabolon Inc 628 (Durham, NC, USA). Proteins from these samples were removed by precipitating them adding 629 methanol and applying vigorous shanking using Glem Mills GenoGrinder 200 and centrifugation. The 630 metabolite identification was carried out under different settings using Waters ACQUITY ultra-631 performance liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high 632 resolution/accurate mass spectrometer (MS) interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. The settings were a reverse 633 phase (RP)/UPLC-MS/MS method with positive-ion mode electrospray ionization (ESI), a RP/UPLC-634 MS/MS with negative ion mode ESI, and a Hydrophilic interaction (HILIC)/UPLC-MS/MS with 635 636 negative ion mode. Then, Metabolon's hardware and software were used to extract the raw data, identify the peaks, and process the specific quality controls. The peak measurement areas for each 637 metabolite were divided by the median peak area of samples in that batch (n=144). The compounds 638 were identified by comparison to Metabolon library, which contains over 3,300 commercially purified 639 640 standards and recurrent unknown entities. Metabolite quantification was performed according to the 641 area-under-the-curve quantification of the corresponding peaks. For each metabolite, if the metabolite measurement failed to reach the detection threshold were imputed from the minimum observed value 642 643 for that metabolite. Each metabolite was assigned to a superpathway, which includes broad metabolic 644 pathway terms, and a subpathway, which includes narrow metabolic pathway terms, during the 645 annotation process. Drug metabolites were categorized as binary variables and the remaining 646 metabolites were natural log plus one (ln+1) transformed.

647 Statistical analysis. Simulation to determine the main statistical model. The statistical method for the 648 models in which CACS was the outcome was selected from simulation data. The simulated dataset 649 was built by shuffling randomly the first delivered data (n=438) to simulate the null hypothesis. We 650 ran 12 models using different transformations in CACS and in microbial species: Linear model with

ln+1 transformation on CACS and microbial species; linear model with bootstrapping standard errors 651 with ln+1 transformation on CACS and microbial species; linear model with bootstrapping based on 652 the residuals with ln+1 transformation on CACS and microbial species; linear model using robust 653 standard errors with ln+1 transformation on CACS and microbial species; linear model with ln+1 on 654 CACS and a center log ratio transformation on the species; negative binomial model with 655 656 bootstrapping standard errors with ln+1 transformation on the microbial species; negative binomial 657 model with ln+1 transformation on microbial species; negative binomial model with center log 658 transformation on the microbial species; hurdle negative model in which we applied a logistic 659 regression in the zero part of the hurdle negative model and a negative binomial model in the count part of the hurdle negative binomial model with the species ln+1 transformed; spearman correlation; 660 ordinal regression with a ln+1 transformation on the microbial species; and a two-step model, in which 661 logistic regression was first applied, followed by a negative binomial for CACS>0 with a ln+1 662 transformed species. The final model was selected according to the performance in the simulation 663 based on the inflation factor and prioritizing methods that allow investigating the associations, in 664 665 accordance with the hypothetical causal diagram created using DAGitty (www.dagitty.net; Extended **Data Fig. 1**) (regression over correlation), and easy interpretation. The linear model using ln+1 666 transformation in CACS and in the gut microbiota species performed well and it was one of the easiest 667 668 regression methods for result interpretation.

669 Association between gut microbiota diversity and atherosclerosis. Alpha and beta diversity were estimated using the R package *vegan*⁷⁹. Alpha diversity was assessed using Shannon diversity index 670 and beta diversity using Bray Curtis dissimilarity. For alpha diversity, we fitted linear regression 671 672 model using CACS as the outcome and adjusting the model for age, sex, country of birth, and technical variables including center site and metagenomics extraction plate within each center site (we 673 674 included an indicator variable for center site and interaction terms between metagenomics extraction plate and center site, but no main effect for metagenomics extraction plate (since this would be 675 redundant)). We further adjusted this model for smoking, physical activity, dietary indicators, and self-676 reported medication for dyslipidemia, hypertension and/or diabetes. For beta diversity, we performed 677

PERMANOVA analyses with 9,999 permutations and assessing the marginal effects of the terms with
beta-diversity as the outcome in the model. The independent variable was the four categories of CACS
and the models were adjusted for the same two set of covariates used in the alpha diversity analyses.
Pairwise comparisons were carried out using PERMANOVA models. Multiple testing was adjusted
for using 5% Benjamini-Hochberg FDR.

Association between gut microbiota species and coronary atherosclerosis. In the discovery cohort, a 683 684 series of linear multivariable regressions using ln+1 of CACS as the dependent variable and ln+1 of 685 the 1,985 microbial species as independent variable. We fitted a model for each species separately. Two sets of covariates were selected according to the assumptions of the causal framework (Extended 686 Data Fig. 1). The basic model was adjusted for age, sex, country of birth, and technical variables 687 including center site, metagenomics extraction plate within each center site and Shannon diversity 688 689 index. The full model was additionally adjusted for smoking, physical activity, ln(total energy intake), In(fiber intake), and medication (self-reported medication prescribed for dyslipidemia, high blood 690 691 pressure, and/or diabetes). Multiple testing was adjusted for using 5% Benjamini-Hochberg FDR. The 692 analyses were performed jointly as well as sex-stratified. To test if the estimate effects were different 693 in the sex-stratified analyses the Cochran's Q-test was used.

We used GSEA from the *fgsea* R package⁸⁰ to determine whether species associated with CACS were enriched for certain genera. This statistical method was applied on the ranked p-values for positive and negative regression coefficients separately of the associations between species and the phenotype of interest in the basic model. The enrichment p-values were controlled using 5% Benjamini–Hochberg FDR.

Sensitivity analysis. Analyses for species significantly associated with CACS were repeated without adjusting for Shannon diversity index. The analyses were also repeated including BMI and PPI drugs as additional covariates in the full model. The full model was also fitted additionally adjusting for traditional cardiovascular risk factors (BMI, diabetes, systolic blood pressure, diastolic blood pressure, total cholesterol, cholesterol in low-density lipoproteins, and cholesterol in high-density lipoproteins) to test if the effect of the gut microbiota species on coronary atherosclerosis was independent of these

705 traditional cardiovascular risk factors. We also performed sensitivity analyses excluding data for participants with Crohn's disease, ulcerative disease and for participants who underwent antibiotic 706 707 treatment during the year preceding their attending the baseline visit. The associations from the main 708 analysis (basic and full model using linear regression) were tested using partial Spearman correlations to ensure consistency using different statistical methods. In case of a discrepancy between the main 709 710 model (linear regression) and the sensitivity model (Spearman correlation) a study of influential 711 observations that may drive the linear association was performed by calculating unscaled dfbeta 712 values. If the most influential observation had higher dfbeta values compared to the regression 713 coefficient and the values were in the same direction as the regression coefficient, the finding from the linear regression was deemed unreliable. The residuals from the association between the species 714 715 considered as reliable and CACS using linear regression were plotted against the exposure to identify 716 any trend between the two variables.

Association between gut microbiota species and carotid atherosclerosis. To assess the association
between CACS-related species and carotid atherosclerosis, a series of ordinal multivariable
regressions were performed using the presence of carotid plaque as the dependent variable for carotid
atherosclerosis and the microbiota species significantly associated with CACS as the independent
variable including only one species in each model. The relative abundance of these species were ln+1
transformed. The models were adjusted using the covariates in the basic and full model. Multiple
testing was adjusted using 5% Benjamini-Hochberg FDR.

724 *Validation in a case-control study with symptomatic atherosclerotic cardiovascular patients.*

Multivariable logistic regressions were fitted with disease status as the binary outcome. The exposure variables were the species with adjusted p-value <0.05 from the basic model used in the discovery cohort that were available in the validation dataset. We did a rank-based inverse normal transformation of the relative abundance of these species for the analysis. The models were adjusted for age, sex and Shannon diversity index. Those associations with a p-value adjusted for Benjamini–Hochberg <0.05 and showing an effect in the same direction as we observed in the discovery cohort were considered as validated. *Functional analysis based on gut metabolic modules.* GSEA was used to assess if species belonging to a specific functional GMM were enriched in their association with CACS compared to species in the other functional models. The analysis was performed on ranked p-values for positive and negative regression coefficients separately, and controlled using 5% Benjamini–Hochberg FDR. To determine if these results were driven by an enrichment of species belonging to a same genus we carried out a repeated GSEA but applying a leave-one-(taxon)-out in the analysis, which consist in removing the species belonging to one genus each time.

Associations between Streptococcus spp. and plasma metabolites. Partial Spearman correlations were

fitted using the R package *ppcor*⁸¹ to assess the correlations between the significant CACS-associated 740 Streptococcus spp. with plasma metabolites controlling for multiple testing using 5% Benjamini– 741 Hochberg FDR. The models were adjusted using the same covariates as previously defined in the full 742 743 model. GSEA was also performed on ranked p-values for positive and negative correlation coefficients separately to evaluate if the streptococci associated with plasma metabolites were enriched for certain 744 745 metabolite subpathway. The enriched p-values were controlled using 5% Benjamini-Hochberg FDR. 746 To investigate the possible mediation effect of these metabolites in the association between 747 Streptococcus spp. and CACS we additionally adjusted the full model for metabolites involved in enriched subpathways with <30% missing values and adjusted p-value <0.05. 748 749 Associations between Streptococcus spp. and systemic inflammatory and infection biomarkers. A 750 series of linear multivariable regressions were fitted to assess the association between CACS-related 751 Strepptococcus spp. (independent variable) and hsCRP and counts of neutrophils and leukocytes 752 (outcomes) controlling for multiple testing using Benjamini-Hochberg at 5% FDR level. The relative 753 abundance of these species were ln+1 transformed, while the outcome variables were natural log 754 transformed. The models were adjusted for the same covariates as the full model. These models further

adjusted for BMI and PPI were also performed.

739

Associations between gut and oral Streptococcus spp. and between oral Streptococcus spp. and oral *health phenotypes.* To investigate the association between CACS-related Streptococcus spp. in the gut
with their homologue in the oral cavity, a series of partial Spearman correlation with cluster-robust

standard errors (family id as a cluster) were fitted adjusted for age, sex, country of birth and gut 759 metagenomics extraction plate. The models were not adjusted for oral metagenomics extraction plate 760 761 because previous quality controls showed no significant effect from the plate on the oral microbiome. The oral *Streptococcus* spp. associated with an adjusted p-value <0.05 with their homologue in the gut 762 were then associated with three oral health phenotypes consisting of filling surfaces, caries and 763 gingival inflammation using ordinal regressions. The oral health phenotypes were the dependent 764 765 variable in the regressions and the ln+1 transformation of the relative abundance of the Streptococcus 766 spp. the independent variable. These ordinal regression with cluster-robust standard errors (family id 767 as a cluster) were adjusted for age, sex, smoking, education, oral hygiene, activity realized the hour before attending to the dental examination, and oral Shannon diversity index. The models were 768 additionally adjusted for BMI, PPI and antibiotic treatment. A 5% Benjamini-Hochberg FDR was 769 770 applied to denote statistical significance in the analyses.

771 Data availability.

The availability of individual data are limited due to the sensitive nature of the data and it can only be
used with previous ethical approval. Therefore, the metagenomics sequences has been anonymized
and they are available in ENA under accession code "PRJEB51353". A subset of anonymized
metabolomics data (n=125) is available in MetaboLights under the study identifier "MTBLS407".
However, all the data used in this work is available from the authors upon reasonable request and with
previous written permission from the Swedish Ethical Review Authority and the SCAPIS Data Access
Board.

779 Code availability.

780 The source code used to generate the results for the analysis is available at

781 <u>https://github.com/MolEpicUU/GUTSY-CACS</u>.

782 Acknowledgements

783 The main financial support for the study was from the European Research Council (ERC-2018-STG-

784 801965 (TF); ERC-CoG-2014-649021 (MO-M) and ERC-STG-2015-679242 (JGS)). Further funding

785	was also provided	from the Swedisl	h Research Counci	(VR 2019-01471	(TF`), 2018-02784 ((MO-M)	
-----	-------------------	------------------	-------------------	----------------	------	-----------------	--------	--

- 786 2018-02837 (MO-M), 2019-01015 (JÄ), 2020-00243 (JÄ), 2019-01236 (GE), 2017-02554 (JGS); and
- 787 EXODIAB 2009-1039 (MO-M)); the Swedish Heart-Lung Foundation [Hjärt-Lungfonden 20190505

788 (TF), 20200711 (MO-M), 20180343 (JÄ), 2019-0526 (JGS), 20200173 (GE)]; the A.L.F.

- 789 governmental grant (2018-0148 (MO-M)); the Novo Nordisk Foundation (NNF20OC0063886 (MO-
- M)); the Swedish Diabetes Foundation (DIA 2018-375 (MO-M)); the Swedish Foundation for
- 791 Strategic Research (LUDC-IRC 15-0067 (MO-M)); Formas (2020-00989 (SA)); Göran Gustafsson
- foundantion [2016 (TF)]; and Axel and Signe Lagerman's foundation (TF),
- 793 The main funding body of The Swedish CArdioPulmonary bioImage Study (SCAPIS) is the Swedish
- Heart-Lung Foundation. The study is also funded by the Knut and Alice Wallenberg Foundation; the
- 795 Swedish Research Council and VINNOVA (Sweden's Innovation agency); the University of
- 796 Gothenburg and Sahlgrenska University Hospital; Karolinska Institutet and Stockholm County
- 797 Council; Linköping University and University Hospital; Lund University and Skåne University
- 798 Hospital; Umeå University and University Hospital; and Uppsala University and University Hospital.
- 799 The main funding body of Malmö Offspring Dental Study (MODS) was Oral Health Related Research
- 800 by Region Skåne (OFRS 422361, OFRS 512951, OFRS 567711, OFRS 655561, OFRS 752071, OFRS
- 801 853031, OFRS 931171 and OFRS968144). The Malmö Offspring Study (MOS) has been funded by
- the Research Council of Sweden (VR 521-2013-2756 (PMN)), the Swedish Heart and Lung
- 803 Foundation [Hjärt-Lungfonden 20150427 (PMN)], and by funds ("ALF") obtained from the local
- 804 Region Skåne County Council (PMN). In addition, funding has been obtained from Ernhold
- 805 Lundströms Stiftelse (LB).
- 806 The computations and data handling were enabled by resources provided by the Swedish National
- 807 Infrastructure for Computing (SNIC) at Uppsala University (SNIC CENTRE) partially funded by the
- 808 Swedish Research Council through grant agreement no. 2018-05973. The computations were
- 809 performed using resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced
- 810 Computational Science (UPPMAX) under Project SNIC sens2019512.

811 Author contributions

- 812 SA, DJ, GE, JGS, JÄ, MO-M and TF obtained the financial support for the study. SS-B, KFD, UH,
- JÄ, MO-M and TF planned and designed the study. LB, AM, LL, GöB, JS, JÄ, GE, JGS, JS, MO-M
- and TF collected the SCAPIS data. LB, PMN, GE and MO-M collected the MOS data. DJ, BK and
- 815 DE planned and collected MODS data. SP, NN, ACE, JBH, HBN preprocessed samples and data and
- 816 carried out the metagenomics bioinformatics analyses. SS-B prepared the R scripts and carried out all
- the associations. SS-B, KFD, DN, DJ, JÄ, MO-M and TF wrote the manuscript. SS-B, GaB and GV
- 818 created the figures. All authors contributed with the critical interpretation of the results and the
- 819 manuscript.

820 Competing interest statement

- 821 The authors declare the following competing interests: S.P, N.N., A.E., J.B.H. and H.B.N. are
- 822 employees for the company Clinical Microbiomics A/S, where the sample processing has been
- 823 performed from DNA extraction to the estimations of relative abundance for the metagenomics
- species. J. Ä. has received lecture fees from Novartis and AstraZeneca, and served on advisory boards
- 825 for AstraZeneca and Boerhinger Ingelheim, all unrelated to the present paper. PMN has received
- 826 lecture fees from Novartis, Novo Nordisk, Amgen and Boerhinger Ingelheim unrelated to the present
- 827 paper. The other authors declare no competing interests.

828 **References**

- Roth, G. A. *et al.* Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019:
 Update From the GBD 2019 Study. *Journal of the American College of Cardiology* **76**, 2982–
 3021 (2020).
- Jonsson, A. L. & Bäckhed, F. Role of gut microbiota in atherosclerosis. *Nature Reviews Cardiology* 14, 79–87 (2017).
- Hashizume-Takizawa, T. *et al.* Oral challenge with Streptococcus sanguinis induces aortic
 inflammation and accelerates atherosclerosis in spontaneously hyperlipidemic mice.
 Biochemical and Biophysical Research Communications 520, 507–513 (2019).
- 4. Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: Human gut microbes
 associated with obesity. *Nature* 444, 1022-1023 (2006).

839 840	5.	Pedersen, H. K. <i>et al.</i> Human gut microbes impact host serum metabolome and insulin sensitivity. <i>Nature</i> 535 , 376–381 (2016).
841 842	6.	Wang, J. <i>et al.</i> A metagenome-wide association study of gut microbiota in type 2 diabetes. <i>Nature</i> 490 , 55–60 (2012).
843 844 845	7.	Liu, S., Zhao, W., Liu, X. & Cheng, L. Metagenomic analysis of the gut microbiome in atherosclerosis patients identify cross-cohort microbial signatures and potential therapeutic target. <i>FASEB Journal</i> 34 , 14166–141681 (2020).
846 847 848	8.	Aryal, S., Alimadadi, A., Manandhar, I., Joe, B. & Cheng, X. Machine learning strategy for gut microbiome-based diagnostic screening of cardiovascular disease. <i>Hypertension</i> 76 , 1555–1562 (2020).
849 850	9.	Liu, F. <i>et al.</i> Alterations of Gut Microbiome in Tibetan Patients With Coronary Heart Disease. <i>Frontiers in Cellular and Infection Microbiology</i> 10 , 373 (2020).
851 852	10.	Zheng, Y. Y. <i>et al.</i> Gut Microbiome-Based Diagnostic Model to Predict Coronary Artery Disease. <i>Journal of Agricultural and Food Chemistry</i> 68 , 3548–57 (2020).
853 854	11.	Toya, T. <i>et al.</i> Coronary artery disease is associated with an altered gut microbiome composition. <i>PLoS ONE</i> 15 , e0227147 (2020).
855 856	12.	Liu, Z. <i>et al.</i> The intestinal microbiota associated with cardiac valve calcification differs from that of coronary artery disease. <i>Atherosclerosis</i> 284 , 121–8 (2019).
857 858	13.	Jie, Z. <i>et al.</i> The gut microbiome in atherosclerotic cardiovascular disease. <i>Nature Communications</i> 8 , 845 (2017).
859 860	14.	Liu, H. <i>et al</i> . Alterations in the gut microbiome and metabolism with coronary artery disease severity. <i>Microbiome</i> 7 , 68 (2019).
861 862	15.	Fromentin, S. <i>et al.</i> Microbiome and metabolome features of the cardiometabolic disease spectrum. <i>Nature Medicine 2022</i> 37 , 1–12 (2022).
863 864	16.	Karlsson, F. H. <i>et al.</i> Symptomatic atherosclerosis is associated with an altered gut metagenome. <i>Nature Communications</i> 3 , 1245–1253 (2012).
865 866	17.	Sattar, N. & Preiss, D. Reverse Causality in Cardiovascular Epidemiological Research: More Common Than Imagined? <i>Circulation</i> 135 , 2369–2372 (2017).
867 868	18.	Bergström, G. <i>et al.</i> The Swedish CArdioPulmonary BioImage Study: Objectives and design. Journal of Internal Medicine 278 , 645–659 (2015).
869 870	19.	Bergström, G. <i>et al.</i> Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. <i>Circulation</i> 144 , 916–929 (2021).
871 872	20.	Li, R. <i>et al.</i> B-Mode-Detected Carotid Artery Plaque in a General Population. Atherosclerosis Risk in Communitites (ARIC) Study Investigators. <i>Stroke</i> 25 , 2377-2383 (1994).
873 874 875	21.	Gepner, A. D. <i>et al.</i> Comparison of Coronary Artery Calcium Presence, Carotid Plaque Presence, and Carotid Intima-Media Thickness for Cardiovascular Disease Prediction in the Multi-Ethnic Study of Atherosclerosis. <i>Circulation: Cardiovascular Imaging</i> 8 , e002262 (2015).
876 877	22.	Persson, M. <i>et al.</i> Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. <i>Stroke</i> 45 , 18–23 (2014).

. Sturlaugsdottir, R. <i>et al.</i> Prevalence and determinants of carotid plaque in the cross-sectional REFINE-Reykjavik study. <i>BMJ Open</i> 6 , e012457 (2016).
. Vieira-Silva, S. <i>et al.</i> Species-function relationships shape ecological properties of the human gut microbiome. <i>Nature Microbiology</i> 1 , 16088 (2016).
. Lemos, J. A. et al. The Biology of Streptococcus mutans. Microbiology Spectrum 7 (2019).
. Iturriaga, G., Suárez, R. & Nova-Franco, B. Trehalose Metabolism: From Osmoprotection to Signaling. International Journal of Molecular Sciences 10 , 3793–3810 (2009).
Lè Ne Tournu, H., Fiori, A. & Dijck, P. van. Relevance of Trehalose in Pathogenicity: Some General Rules, Yet Many Exceptions. <i>PLoS Pathogens</i> 9, e1003447 (2013).
 Jönsson, D. <i>et al.</i> Periodontal disease is associated with carotid plaque area: the Malmö Offspring Dental Study (MODS). <i>Journal of Internal Medicine</i> 287, 301–309 (2020).
Ma, J. & Li, H. The Role of Gut Microbiota in Atherosclerosis and Hypertension. <i>Frontiers in Pharmacology</i> 9 , 1082 (2018).
 Doern, C. D. & Burnham, CA. D. It's Not Easy Being Green: the Viridans Group Streptococci, with a Focus on Pediatric Clinical Manifestations. <i>Journal of Clinical Microbiology</i> 48, 3829 (2010).
. Ott, S. J. <i>et al.</i> Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. <i>Circulation</i> 113 , 929–937 (2006).
. Koren, O. <i>et al.</i> Human oral, gut, and plaque microbiota in patients with atherosclerosis. <i>Proceedings of the National Academy of Sciences</i> 108 , 4592–4598 (2011).
. Viehman, J. A. <i>et al.</i> Chapter 3 - Microbiology of endocarditis. in Infective Endocarditis 43-59 (ed. Kilic A, 2022).
. Kesavalu, L. <i>et al.</i> Increased atherogenesis during Streptococcus mutans infection in ApoE-null mice. <i>Journal of Dental Research</i> 91 , 255–260 (2012).
Brandsma, E. <i>et al.</i> A Proinflammatory Gut Microbiota Increases Systemic Inflammation and Accelerates Atherosclerosis. <i>Circulation Research</i> 124 , 94–100 (2019).
Razonable, R. R. <i>et al.</i> Bacteremia due to viridans group streptococi with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. <i>Clinical Infectious Diseases</i> 34, 1469–1474 (2002).
Chia, J. S. <i>et al.</i> Induction of Cytokines by Glucosyltransferases of Streptococcus mutans. <i>Clinical and Diagnostic Laboratory Immunology</i> 9 , 892-897 (2002).
Chhibber-Goel, J. <i>et al.</i> Linkages between oral commensal bacteria and atherosclerotic plaques in coronary artery disease patients. <i>npj Biofilms and Microbiomes</i> 2 , 7 (2016).
 Lanter, B. B. & Davies, D. G. Propionibacterium acnes recovered from atherosclerotic human carotid arteries undergoes biofilm dispersion and releases lipolytic and proteolytic enzymes in response to norepinephrine challenge In vitro. <i>Infection and Immunity</i> 83, 3960–3971 (2015)
 Nagata, E., de Toledo, A. & Oho, T. Invasion of human aortic endothelial cells by oral viridans group streptococci and induction of inflammatory cytokine production. <i>Molecular Oral</i> <i>Microbiology</i> 26, 78–88 (2011).

917 918 919	41.	Snow, D. E. <i>et al.</i> The presence of biofilm structures in atherosclerotic plaques of arteries from legs amputated as a complication of diabetic foot ulcers. <i>Journal Wound Care</i> 25 , S16–S22 (2016).
920 921	42.	Leishman, S. J., Do, H. L. & Ford, P. J. Cardiovascular disease and the role of oral bacteria. Journal of Oral Microbiology 2 (2010).
922 923	43.	Nakano, K. & Ooshima, T. Common knowledge regarding prevention of infective endocarditis among general dentists in Japan. <i>Journal of Cardiology</i> 57 , 123–130 (2011).
924 925	44.	Yumoto, H. <i>et al.</i> The Pathogenic Factors from Oral Streptococci for Systemic Diseases. International Journal of Molecular Sciences 20 , 4571 (2019).
926 927	45.	Nomura, R. <i>et al.</i> Contribution of Severe Dental Caries Induced by Streptococcus mutans to the Pathogenicity of Infective Endocarditis. <i>Infection and Immunity</i> 88 , e00897 (2020).
928 929 930	46.	Kim, K. <i>et al.</i> Severity of dental caries and risk of coronary heart disease in middle-aged men and women: a population-based cohort study of Korean adults, 2002–2013. <i>Scientific Reports</i> 9 , 1–7 (2019).
931 932 933 934	47.	Kilian, M. Streptococcus and enterococcus: Pharyngitis; scarlet fever; skin and soft tissue infections; streptococcal toxic shock syndrome; pneumonia; meningitis; urinary tract infections; rheumatic fever; post-streptococcal glomerulonephritis. in <i>Medical Microbiology: Eighteenth Edition</i> 183–198 (Elsevier Inc., 2012).
935 936	48.	Rafferty, B. <i>et al.</i> Impact of monocytic cells on recovery of uncultivable bacteria from atherosclerotic lesions. <i>Journal of Internal Medicine</i> 270 , 273–280 (2011).
937 938	49.	Sethi, N., Safi, S., Korang, S. & Hróbjartsson, A. Antibiotics for secondary prevention of coronary heart disease. <i>Cochrane Database Systemic Reviews</i> 2021 , CD003610 (2021).
939 940 941	50.	Jespersen, C. M. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. <i>British Medical Journal</i> 332 , 22–24 (2006).
942 943	51.	Sharma, D. & Khan, A. U. Antibiotics versus biofilm: an emerging battleground in microbial communities. Antimicrobial Resistance and Infection Control 8 , 76 (2019).
944 945	52.	Brown, J. M. & Hazen, S. L. Microbial modulation of cardiovascular disease. <i>Nature Reviews Microbiology</i> 16 , 171–181 (2018).
946 947 948	53.	Zhang, B. C. <i>et al.</i> Increased serum bile acid level is associated with high-risk coronary artery plaques in an asymptomatic population detected by coronary computed tomography angiography. <i>Journal of Thoracic Disease</i> 11 , 5063–5070 (2019).
949 950 951	54.	Steiner, C. <i>et al.</i> Bile Acid Metabolites in Serum: Intraindividual Variation and Associations with Coronary Heart Disease, Metabolic Syndrome and Diabetes Mellitus. <i>PLOS ONE</i> 6 , e25006 (2011).
952 953	55.	Charach, G. <i>et al.</i> The association of bile acid excretion and atherosclerotic coronary artery disease. <i>Therapeutic Advances in Gastroenterology</i> 4 , 95 (2011).
954 955	56.	Cross, T. W. L., Kasahara, K. & Rey, F. E. Sexual dimorphism of cardiometabolic dysfunction: Gut microbiome in the play? <i>Molecular Metabolism</i> 15 , 70-81 (2018).

956 957	57.	Ohlsson, C., Vandenput, L. & Tivesten. DHEA and mortality: What is the nature of the association? <i>The Journal of Steroid Biochemistry and Molecular Biology</i> 145 , 248–253 (2015).
958 959 960	58.	Poss, A. M. <i>et al.</i> Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease. <i>The Journal of Clinical Investigation</i> 130 , 1363–1376 (2020).
961 962	59.	Ganna, A. <i>et al.</i> Large-scale Metabolomic Profiling Identifies Novel Biomarkers for Incident Coronary Heart Disease. <i>PLOS Genetics</i> 10 , e1004801 (2014).
963 964	60.	Ottosson, F. <i>et al.</i> A plasma lipid signature predicts incident coronary artery disease. International Journal of Cardiology 331 , 249–254 (2021).
965 966 967	61.	Nelson, J. C., Jiang, X. C., Tabas, I., Tall, A. & Shea, S. Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. <i>American Journal of Epidemiology</i> 163 , 903–912 (2006).
968 969	62.	Sigruener, A. <i>et al.</i> Glycerophospholipid and Sphingolipid Species and Mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. <i>PLOS ONE</i> 9 , e85724 (2014).
970 971	63.	Yu, Z., Peng, Q. & Huang, Y. Potential therapeutic targets for atherosclerosis in sphingolipid metabolism. <i>Clinical Science</i> 133 , 763 (2019).
972 973 974	64.	S Leite, G. G. <i>et al.</i> Mapping the Segmental Microbiomes in the Human Small Bowel in Comparison with Stool: A REIMAGINE Study. <i>Digestive Diseases and Sciences</i> 65 , 2595–2604 (2020).
975 976	65.	Pasolli, E. <i>et al</i> . Accessible, curated metagenomic data through ExperimentHub. <i>Nature Methods</i> 14 , 1023–24 (2017).
977 978	66.	Brunkwall, L. <i>et al</i> . The Malmö Offspring Study (MOS): design, methods and first results. <i>European Journal of Epidemiology</i> 36 , 103–116 (2021).
979 980 981 982	67.	Touboul, P. J. <i>et al.</i> Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004–2006–2011): An Update on Behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. <i>Cerebrovascular Disease</i> 34 , 290 (2012).
983 984	68.	Löe, H. The Gingival Index, the Plaque Index and the Retention Index Systems. The <i>Journal of Periodontology</i> 38 , 610–616 (1967).
985 986	69.	Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. <i>Nature Methods 2012 9:4</i> 9 , 357–359 (2012).
987 988 989	70.	Pasolli, E. <i>et al.</i> Extensive Unexplored Human Microbiome Diversity Revealed by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. <i>Cell</i> 176 , 649-662.e20 (2019).
990 991	71.	Li, D. <i>et al.</i> MEGAHIT v1.0: A fast and scalable metagenome assembler driven by advanced methodologies and community practices. <i>Methods</i> 102 , 3–11 (2016).
992 993 994	72.	Li, D., Liu, C. M., Luo, R., Sadakane, K. & Lam, T. W. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. <i>Bioinformatics</i> 31 , 1674–1676 (2015).

995	73.	Steinegger M. & Söding J. Clustering huge protein sequence sets in linear time. Nature
996		Communications 9 , 2542 (2018).

- 997 74. Nielsen, H. B. *et al.* Identification and assembly of genomes and genetic elements in complex
 998 metagenomic samples without using reference genomes. *Nature Biotechnology* 32, 822–828
 999 (2014).
- 1000 75. O'Leary, N. A. *et al.* Reference sequence (RefSeq) database at NCBI: current status, taxonomic
 1001 expansion, and functional annotation. *Nucleic Acids Research* 44, D733–D745 (2016).
- 1002 76. Huerta-Cepas, J. *et al.* eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated
 1003 orthology resource based on 5090 organisms and 2502 viruses. *Nucleic Acids Research* 47,
 1004 D309–D314 (2019).
- 1005 77. Cantalapiedra, C. P., Hernández-Plaza, A., Letunic, I., Bork, P. & Huerta-Cepas, J. eggNOG1006 mapper v2: Functional Annotation, Orthology Assignments, and Domain Prediction at the
 1007 Metagenomic Scale. *Molecular Biology and Evolution* **38**, 5825–5829 (2021).
- 1008 78. Evans, A. M., DeHaven, C. D., Barrett, T., Mitchell, M. & Milgram, E. Integrated, nontargeted
 1009 ultrahigh performance liquid chromatography/ electrospray ionization tandem mass
 1010 spectrometry platform for the identification and relative quantification of the small-molecule
 1011 complement of biological systems. *Analytical Chemistry* 81, 6656–6667 (2009).
- 1012 79. Oksanen, J. *et al.* vegan: Community Ecology Package. R package version 2.5-7.
 1013 https://CRAN.R-project.org/package=vegan. (2020).
- 1014 80. Korotkevich, G. *et al.* Fast gene set enrichment analysis. *bioRxiv* (2021).
- 1015 81. Kim, S. ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients.
 1016 Communications for Statistical Applications and Methods 22, 665–674 (2015).
- 1017

1018

Table 1 Descriptive characteristics of participants in the discovery cohort (SCAPIS study)

	Malmö	Uppsala
	n=4,541	n=4,432
CACS ^{†‡}	0.00 [0.00; 27.0]	0.00 [0.00; 15.0]
Clinical CACS, n (%) [‡] :		
0	2,574 (56.7)	2,781 (62.7)
1–100	1,379 (30.4)	1,187 (26.8)
101-400	398 (8.76)	319 (7.20)
>400	190 (4.18)	145 (3.27)
Carotid arteries with identified plaques, n (%):		
None	1,862 (41.1)	1,959 (44.2)
Unilateral	1,388 (30.7)	1,391 (31.4)
Bilateral	1,275 (28.2)	1,080 (24.4)
Age (years)*	57.3 (4.28)	57.6 (4.39)
Sex, female, n (%)	2,480 (54.6)	2,336 (52.7)
Country of birth, n (%):		
Scandinavia	3,575 (78.7)	4,001 (90.3)
Asia	237 (5.22)	170 (3.84)
Rest of Europe	629 (13.9)	165 (3.72)
Other	100 (2.20)	96 (2.17)
Triglycerides, mmol/L ^{\dagger}	1.10 [0.80; 1.50]	1.09 [0.83; 1.53]
LDL cholesterol, mg/L* ^{\ddagger}	3.64 (0.94)	3.57 (0.92)
HDL cholesterol, mmol/L ^{†‡}	1.60 [1.30; 2.00]	1.40 [1.20; 1.70]
Total cholesterol*	5.48 (1.00)	5.73 (1.05)
SBP, mmHG* [‡]	122 (16.4)	125 (15.9)
DBP, mmHG* [‡]	75 (9.65)	77 (9.79)

BMI, kg/m ^{2‡}	27.2 (4.58)	27.0 (4.36)
HsCRP, mmol/L ^{†‡}	1.20 [0.60; 2.40]	1.20 [0.59; 2.30]
Neutrophil counts* $10^9/L^{\dagger}$	3.00 [2.40; 3.80]	2.80 [2.30; 3.50]
Leukocyte counts* $10^9/L^{\dagger}$	5.60 [4.70; 6.70]	5.30 [4.60; 6.30]
Total energy intake, Kcal/day [†]	1,578 [1,220; 2,066]	1,612 [1,268; 2,048]
Fiber intake, g/day [†]	11.3 [8.58; 14.2]	11.5 [9.01; 14.1]
Diabetes, n (%)	198 (4.55)	171 (4.07)
Crohn's and ulcerative disease, n (%):	43 (1.00)	52 (1.24)
Medication for dyslipidemia, n (%)	292 (6.71)	274 (6.53)
Medication for high blood pressure, n (%)	834 (19.2)	764 (18.2)
Medication for diabetes, n (%)	165 (3.80)	140 (3.34)
Proton pump inhibitor, n (%)	159 (4.51)	122 (2.78)
Antibiotic treatment (J01 class), n (%)	931 (20.5)	819 (18.5)
Smoking, n (%):		
Never smoker	1,948 (44.0)	2,469 (58.6)
Former smoker	1,681 (38.0)	1,351 (32.1)
Current smoker	795 (18.0)	394 (9.35)
Physical activity in leisure time, n (%):		
Sedentary	594 (13.8)	425 (10.2)
Moderate exercise	2,107 (48.9)	1,873 (45.1)
Moderate but regular exercise	1,114 (25.8)	1,357 (32.7)
Regular exercise and training	498 (11.5)	496 (11.9)

1020

1021 * Mean (standard deviation).

1022 [†] Median [interquartile range].

1023 [‡] CACS, coronary artery calcium score; LDL, low-density lipoprotein; HDL, high-density lipoprotein;

- 1024 SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; hsCRP, high-
- 1025 sensitivity C-reactive protein.

1026 Fig. 1 Beta diversity across the coronary artery calcium score (CACS) categories. Representation

1027 of the two principal coordinates (PCo) based on Bray-Curtis dissimilarity between individuals colored

- 1028 according to clinical categories of CACS, a measure of asymptomatic atherosclerosis. The centroid of
- 1029 the two first coordinates is shown as a triangle. Absent: CACS=0; Mild: 1≤CACS<101; Moderate:
- 1030 101 ≤ CACS < 401; and Extensive: CACS > 400.
- 1031



1032

Fig. 2 Metagenomic species associated with coronary artery calcium score (CACS) in the basic model and the full model showed an overrepresentation of Streptococcus spp. a, Cladogram of species associated with CACS with a p-value <0.05 (unadjusted for multiple testing) in the basic model. Blue shade indicates the genera overrepresented (FDR<5%) in the enrichment analysis using gene-set enrichment analysis. Only the metagenomics species identified at least to species level were highlighted. Red circles indicate the streptococcal species associated with CACS in the full model (FDR<5%). Turquoise circles indicate the non-streptococcal species associated with CACS in the full model (FDR<5%). b, Volcano plot representing all the associations between species and CACS in basic model. Red dots indicate the significant streptococcal species associated with CACS (FDR<5%), turquoise dots indicate significant non-streptococcal species associated with CACS (FDR<5%), and grey dots indicate the associations between non-significant species and CACS (FDR>5%). c. Dot plot showing the results of the enrichment analysis using gene-set enrichment analysis at genus level using the ranked p-values with positive regression coefficients of the associations between species and CACS in the basic model. Modules with less than 15 elements were removed from the plot to improve the visualization. Streptococcus was the only enriched genus (FDR<5%) and it is indicated with a blue dot. d, Forest plot of the *Streptococcus* spp. associated with CACS in the basic mode and full model with FDR<5%. The dots represent the estimate of the association between the *Streptococcus* spp. and the CACS, and the bar represents the 95% confidence intervals. The estimates and the confidence intervals were $\ln(x+10)$ -1 transformed to improve the figure visualization. Orange color represents sex-combined analysis, purple color represents results for the female population, and blue color represents results for the male population. The * indicates the existence of a sex-effect modification in the association between the Streptococcus spp. and the CACS (unadjusted for multiple testing).



Fig. 3 Heatmaps of associations between CACS-related gut Streptococcus spp. and plasma metabolites subpathways, inflammatory and infection markers, and oral Streptococcus spp. related to oral health phenotypes. a, Heatmap showing the enrichment of metabolite sub-pathways based in full adjusted associations between CACSrelated gut Streptococcus spp. and plasma metabolites. Blue represents the normalized enrichment score (NES) on the enrichment analysis for the negative associations between the *Streptococcus* spp. and plasma metabolites and red represents the NES on the enrichment analysis based on the positive associations. Significant enrichments at 5% FDR are displayed with an asterisk (*). b, Heatmap showing linear associations between CACS-related gut Streptococcus spp. and three inflammatory markers (hsCRP: high-sensitivity C-reactive protein, neutrophils and leukocytes) adjusted for age, sex, country of birth, center site, metagenomics extraction plate within the center site, Shannon diversity index, smoking, physical activity, fiber and total energy intake, and self-reported medication for dyslipidemia, hypertension and/or diabetes. The three inflammatory markers were scaled to mean of 0 and standard deviation of 1. The heatmap is colored based on the magnitude of the linear correlation coefficient. Significant associations at 5% FDR are displayed with an asterisk (*). c) Heatmap showing the associations between oral CACS-related gut Streptococcus spp. and three oral health phenotypes (Filled surface, Caries and Gingival inflammation) adjusted for age, sex, smoking, education, oral hygiene, activity realized the hour before attending to the dental examination, and Shannon diversity index. The heatmap is colored based on the natural logarithm of the odds ratio (ln(odds ratio)). Significant associations at 5% FDR are displayed with an asterisk (*).



Extended Data Fig. 1 Directed acyclic graph of the assumed framework in the associations between the gut microbiome and atherosclerosis. The graph was generated in DAGitty v3.0 assuming gut microbiota species are causally associated with atherosclerosis. A directed edge (or "arrow") from one node to another represents a direct effect between these two nodes. Red circles represent confounder variables, blue circles mediator variables, green circles technical source of variation, and grey circles unobserved variables. BP, blood pressure; Dyslipidemia Med, medication for dyslipidemia; Diabetes Med, medication for diabetes; BP med, medication for blood pressure; BMI, body mass index; PA, physical activity.



Extended Data Fig. 2 Quantile-quantile plot (qq-plot) of p-values from simulation studies performed prior to the analysis of the relationship between species and coronary artery calcium score (CACS). The first data delivered from Clinical Microbiomics A/S (n=438) was shuffled randomly to create a simulation dataset with maintained variable distribution. The y axis has been truncated at 10 units to improve the visualization of the qq-plots. Then, 12 models were tested to compare their performance in the dataset and are depicted in the qq-plot. Boot.Im, linear model with bootstrapping standard errors; boot.Im.resi, linear model with bootstrapping based on the residuals; boot.nb; negative binomial model with bootstrapping standard errors; hurdle.nb.count, the count part of the hurdle negative binomial model; hurdle.nb.zero, the zero part of the hurdle negative binomial model; lin.clr, linear model transforming the species data using center log ratio transformation; lm.log1p , linear model transforming the species data using center log ratio transformation; ordinal, ordinal regression model, robust.lm, linear model using robust standard errors; spearman, partial spearman correlation; two.stage.count, linear model on the counts different to zero after a first step using natural logistic regression; and two.stage.zero, logistic regression applied before a second step using linear regression on the counts different to zero.



Extended Data Fig. 3 Scatterplot showing the correlation between the estimates and the p-values of the basic model and the full model in 8,155 participants with complete data on all covariates. Blue line indicates the linear regression showing a slightly lower slope compared to the black line, which represents the regression with slope =1. The Pearson correlation (R) between the main model and the sensitivity model is displayed in the figure.



Extended Data Fig. 4 Scatterplot showing the correlation between the main analysis using basic and full models and sensitivity models excluding participants with Crohn's disease, antibiotic drug users, without adjusting for Shannon diversity index, and after adjusting the full model for body mass index (BMI), participants receiving proton-pump inhibitors (PPI) and/or established cardiovascular risk factors (CVRF). Blue lines indicate the linear regression and the black lines represent the regression with slope =1. The Pearson correlation (R) between the main model and the sensitivity model is displayed in the figure.



Extended Data Fig. 5 Forest plot of the species associated with CACS showing sex-effect modification with pvalue <0.05 (unadjusted for multiple testing) in the full model. The dot represents the estimate of the association between the species and the CACS, and the bar represents the 95% confidence interval. Orange color represents sexcombined analysis, purple color represents results for the female population, and blue color represents results for the male population.



Extended data Fig. 6 The distribution of fifteen species associated with increased coronary artery calcium score in the SCAPIS study over 210 cases and 163 controls of symptomatic atherosclerotic cardiovascular disease in the case-control study by Jie Z et al. The species were identified using the same gene signature as in SCAPIS and the resulting relative abundance were rank-based inverse normal transformed.

3 Rank-Based Inverse Normal Transformation (Relative abundance) Eupacleriales EP. HG3P. 0854 ndon'i S. nutaris S. oralis subsp. oralis S. oralis subsp. oralis S. parasanguinis S. salivarius Reinuciaginosa Riorques Sagaaciae Sanginosus Soordonii Lesalivarius L.98558ri L.Iactis

🖨 Control 🖨 ACVD

Extended data Fig. 7 Functional gut metabolic modules (GMM) enriched on the positive associations between species and CACS in the basic model. a, Dot plot showing the results of the enrichment analysis using gene-set enrichment analysis (GSEA) to identify functional GMM using the ranked p-values of the positive associations between species and CACS in the basic model. Blue dots indicate the enriched GMM. **b**, Dot plot showing the results of the enrichment analysis using gene-set enrichment analysis (GSEA) to identify functional GMM using the ranked p-values of the negative associations between species and CACS in the basic model. Orange dots indicate the enriched GMM. **c**, GSEA applying leave-one (taxon)-out analysis removing one genus at a time for each enriched GMM. Red dots indicate the analysis removing *Streptococcus* genus and the black lines indicate the enrichment analysis without removing any genus. The genera indicated in the figure are the two removed genus that causes lower normalized enrichment score (NES) or the two removed genus that causes higher normalized enrichment score (NES).



Extended data Fig. 8 Correlations between CACS-associated species and plasma metabolites of enriched metabolic sub-pathways. a, Heatmap showing the partial Spearman correlations between CACS-associated *Streptococcus* spp. and plasma metabolites involved in the significantly enriched metabolic sub-pathway based on the ranked p-values of positive associations adjusted for the covariates used in the full model (model adjusted for age, sex, country of birth, smoking, physical activity, total energy intake, fiber intake, self-reported medication prescribed for dyslipidemia, high blood pressure, and/or diabetes, and technical variables including center site, metagenomics extraction plate and Shannon diversity index). The asterisk (*) indicates the associations significant at 5% FDR. b, Heatmap showing the partial Spearman correlations between CACS-associated *Streptococcus* spp. and plasma metabolites involved in the significantly enriched metabolic sub-pathway based on the ranked p-values of negative associations adjusted for the covariates used in the full model. The asterisk (*) indicates the associations significant at 5% FDR.



Extended data Fig. 9 Scatterplot showing the correlation between the estimates and the p-values of the associations between *Streptococcus* spp. and CACS in the full model (n=5,683) with and without adjustment for metabolites with <30% missing data involved in sub-pathways related to primary and secondary bile acids metabolism, acetylated peptides, plasmalogen, androgenic steroids, sphingomyelins, analgesic and anesthetic drugs, and/or partially characterized molecules; and the same analysis but restricting the analysis to those participants with complete data. Blue lines indicate the linear regression and the black lines represent the regression with slope =1. The Pearson correlation (R) between the main model and the sensitivity model is displayed in the figure.



0

2 4 -log10(Complete Cases Model)

0

0

10 Complete Cases Model

20

6

Extended data Fig. 10 Directed acyclic graph of the hypothetical causal framework in the association between the oral *Streptococcus* spp. and three phenotypes of oral health (filled surface, caries and gingival inflammation). The graph was generated in DAGitty v3.0 assuming causal association between *Streptococcus* spp. and oral health. A directed edge (or "arrow") from one node to another represents a direct effect between these two nodes. Red circles represent confounder variables, blue circles mediator variables, and green circles technical source of variation. Dyslipidemia Med, medication for dyslipidemia; and Last Hour Act, activity realized the hour before attending to the dental examination.

